Agree Realty (ADC) Q2 2025 Earnings Call August 01, 2025 09:00 AM ET Company ParticipantsReuben Treatman - Senior Director - Corporate FinanceJoey Agree - President, CEO & DirectorPeter Coughenour - CFOKi Bin Kim - MD - US REIT Equity ResearchSmedes Rose - DirectorJana Galan - DirectorSheryl Kaul - Equity Research AssociateBrad Heffern - DirectorRich Hightower - MD - U.S. REIT ResearchJames Kammert - Managing DirectorSamuel A.A. Ohiomah - Senior Research Associate - REITsRonald Kamdem - MD & Head - US REITs ...

Financial Data and Key Metrics Changes - The company invested over $725 million across its three external growth platforms in the first half of the year, representing more than a twofold increase compared to the same period last year [5] - Core FFO per share was $1.05 for Q2, a 1.3% increase year-over-year, while AFFO per share was $1.06, reflecting a 1.7% year-over-year increase [19] - The full year AFFO per share guidance was raised to a range of $4.29 to $4.32, indicating over 4% growth at the midpoint [8][19] Business Line Data and Key Metrics Changes - In Q2, the company invested over $350 million in 110 properties, including $328 million in acquisition volume across 91 high-quality retail net lease assets [10] - The weighted average cap rate of acquired properties was 7.1%, with a weighted average lease term of 12.2 years [11] - The company executed new leases, extensions, or options on approximately 950,000 square feet of gross leasable area during the quarter, with a recapture rate of approximately 104% [13] Market Data and Key Metrics Changes - The company noted the highest level of retailer demand for new brick-and-mortar locations since the Great Financial Crisis, with nearly every retailer focused on adding net new stores [10] - The investment grade exposure stood at 68%, and occupancy rebounded to 99.6% post re-tenanting of former Big Lots [14] Company Strategy and Development Direction - The company is focused on maintaining a dominant market position through a best-in-class team and a robust asset management platform [6] - The company anticipates a significant ramp-up in development spending, expecting at least a 50% year-over-year increase [12] - The strategic focus remains on core durable goods and necessity-based retailers, avoiding discretionary and experiential sectors [30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to provide consistent earnings growth without deviating from the investment strategy, despite a deteriorating consumer sentiment [30] - The company is well-positioned with over $2.3 billion in total liquidity and no material debt maturities until 2028, supporting growth into the next year [7][18] Other Important Information - The company raised over $1 billion in capital year-to-date, with total capital markets activity exceeding $1.3 billion [17] - The monthly cash dividend declared for Q2 was $0.0256 per common share, representing a 2.4% year-over-year increase [22] Q&A Session Summary Question: Can you give us some color about your ATM activity in 2Q and overall timing given your overnight equity offering in late April? - The ATM activity during the quarter all predated the overnight offering in April, and the company promised to remain inactive in the capital markets post-offering [26][27] Question: What’s the magnitude of acquisition cap rates going forward? - The company anticipates acquisition cap rates to expand but will remain focused within their established tenant base [28] Question: How are you thinking about retailer and consumer health right now? - Consumer health has deteriorated, but the focus remains on core durable goods and necessity-based retailers, which are expected to gain market share [30][32] Question: Can you talk about some of the opportunities in the DFT business for developments? - The company plans to break ground on a minimum of $100 million in projects before year-end, with a significant shadow pipeline [39][40] Question: Is there an upper limit on investment in the development platform? - The company has set a three-year goal of investing $250 million annually in development, with no speculative development planned [60][62] Question: What is the status of your watch list? - The watch list is minimal, primarily focused on At Home and a few movie theaters, with no significant credit issues anticipated [86][89]

RESTON, Va., Aug. 1, 2025 /PRNewswire/ -- V2X, Inc. (NYSE: VVX), has been awarded a $4.3 billion indefinite-delivery/indefinite-quantity contract by the U.S. Air Force for Contractor Operated and Maintained Supply services in support of the T-6 aircraft.This contract provides supply support for safe, flyable aircraft to meet the daily flight schedules and depot requirements of the U.S. Air Force, Navy, and Army. The effort aligns with Department of Defense and commercial best practices for procuring, produc ...

Universal Display (OLED) Q2 2025 Earnings Call July 31, 2025 05:00 PM ET Speaker0Good day, ladies and gentlemen, and welcome Universal Display Corporation's Second Quarter twenty twenty five Earnings Conference Call. My name is Sherry, and I will be your conference moderator for today's call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded for replay purposes.I would now like to turn ...

Core Insights - Fresenius Medical Care announced a collaboration involving Frenova, Nephronomics, and GENEWIZ to enhance genomic analysis for the My Reason® genomics research program, focusing on kidney, cardiovascular, and metabolic diseases [1][3][6] Group 1: Collaboration Details - The collaboration aims to leverage advanced technologies for a better understanding of kidney and related diseases, driving advancements in precision medicine [1][4] - Frenova's My Reason® program has registered over 35,000 participants, with a goal of reaching 50,000 in the next two years, focusing on genomic and clinical data to uncover insights into kidney disease [3][4] - Nephronomics holds exclusive commercial rights to the My Reason® dataset, which is integral to the Nephronomics Atlas, aimed at developing targeted therapies through precision medicine insights [4][11] Group 2: Technological Contributions - GENEWIZ will utilize its DNA sequencing technologies to generate large-scale genomic data from biospecimens collected through Frenova's nephrology research network [5][6] - Azenta will provide long-term storage solutions for the samples, enhancing the research capabilities of the collaboration [5][6] Group 3: Industry Context - Fresenius Medical Care is a leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally [7] - The collaboration represents a significant step forward in advancing precision medicine and improving patient outcomes in the cardio-kidney-metabolic field [4][6]

From Metaverse to Machine Learning, Inside Meta’s $72 Billion AI Gamble► https://t.co/04yW6mcZMm https://t.co/04yW6mcZMm ...

MiMedx Group (MDXG) Q2 2025 Earnings Call July 30, 2025 04:30 PM ET Speaker0Good afternoon, and thank you for standing by. Welcome to the Mimetics Second Quarter twenty twenty five Operating and Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded.I would now like to turn the conference over to Mr. Matt Matoriani, Head of Investor Relations for Mimetics. ...

Core Insights - Qorvo reported Q1 FY2026 earnings with GAAP revenue of $818.8 million and non-GAAP diluted EPS of $0.92, both missing analyst estimates of $868.8 million and $1.13 respectively [1][5] - Non-GAAP gross margin improved to 44.0%, up 3.1 percentage points year-over-year, indicating stronger profitability despite soft sales [1][6] Financial Performance - Q1 FY2026 diluted EPS (Non-GAAP) was $0.92, below the estimate of $1.13 but up 5.7% from $0.87 in Q1 FY2025 [2] - GAAP revenue decreased by 7.7% year-over-year from $886.7 million in Q1 FY2025 to $818.8 million in Q1 FY2026 [2] - Non-GAAP operating income rose 10.3% to $108.2 million compared to $98.1 million in Q1 FY2025 [2][6] - Free cash flow surged to $145.4 million, a 339% increase from $42.85 million in Q1 FY2025 [2][6] Business Focus and Strategy - Qorvo is concentrating on enhancing its R&D pipeline, strengthening customer relationships, and scaling high-value operations while reducing exposure to lower-margin segments [4] - The company is prioritizing new design wins in power management ICs, automotive ultra-wideband chips, and defense electronics [4] - Qorvo's customer base is heavily concentrated, with Apple and Samsung accounting for significant portions of sales, which poses challenges during periods of low demand [5] Segment Performance - The High Performance Analog (HPA) unit reported a 6.1% year-over-year revenue increase to $137.4 million [8] - The Connectivity & Sensors Group (CSG) saw revenue decline by 4.1% to $110.2 million but improved its operating loss from $19.5 million to $7.5 million [8] - The Advanced Cellular Group (ACG) experienced an 11.1% revenue decline to $571.2 million, attributed to weaker demand and a strategic pullback from the low-tier Android market [8] Product Development - Qorvo is investing in technologies for faster wireless data and improved battery efficiency, focusing on GaAs, GaN, BAW, and SAW technologies [9] - The company is advancing its power management ICs and ultra-wideband chips, leveraging AI and machine learning for enhanced product performance [9] Future Outlook - Management projects Q2 FY2026 revenue of approximately $1.025 billion, with non-GAAP gross margin expected to rise to 48% to 50% and non-GAAP EPS to reach $2.00 [10] - Growth is anticipated to be driven by new customer device launches, particularly from major accounts [10]

Q2 2025 Financial Results July 30, 2025 1 Forward-looking Statements 2 This presentation contains forward-looking statements within the meaning of the federal securities laws. Forward-looking statements include but are not limited to statements relating to: our financial guidance for the third quarter of 2025 and underlying assumptions; our customer relationship flywheel; the impact of AI, ML, and LLMs; our ability to become a leader in agentic shopping; our product development investments and marketing ini ...

Core Insights - Super X AI Technology Limited has launched its flagship product, the SuperX XN9160-B200 AI Server, designed to meet the increasing demand for high-performance computing in AI training and machine learning workloads [1][3] Product Features - The XN9160-B200 AI Server is optimized for large-scale distributed AI training and inference, supporting GPU-intensive tasks and applications such as climate modeling and drug discovery [2][4] - It features 8 NVIDIA Blackwell B200 GPUs, fifth-generation NVLink technology, 1440 GB of HBM3E memory, and 6th Gen Intel® Xeon® processors, all within a compact 10U chassis [4][5] - The server achieves up to a 3x speed improvement in AI model training and a throughput of 58 tokens per second per card on the GPT-MoE 1.8T model, representing a performance increase of up to 15x compared to the previous generation [5][6] Reliability and Support - The XN9160-B200 includes a multi-path power redundancy solution to ensure operational reliability, with redundant power supplies to mitigate risks of failures [7] - It is equipped with an intelligent management system for remote monitoring and management, and each server undergoes extensive testing to ensure reliability [8] Market Positioning - The XN9160-B200 is targeted at global enterprises and research institutions with demanding compute needs, including sectors like finance, healthcare, and government [10][12]